Novo Nordisk ® ncluding the statutory An nual Report 2021 and Form 20-F, which both were filed with the SEC in ritten information released, or oral statements made, to the public in the future by or on behalf of plan’, ‘strategy’, ‘prospect’, ‘foresee’, ‘estimate’, ‘project’, ‘anticipate’, ‘can’, ‘intend’, ‘target’ and other l performance identify forward-looking statements. Examples of such forward-looking statements Novo Nordisk’s products, product research, product development, product introductions and er share, capital expenditures, dividends, capital structure, net financials and other financial es such as legal proceedings, and d-looking statements involve inherent risks and uncertainties, both general and specific. Novo ould cause actual results to differ materially from those contemplated in any forward-looking d economic conditions, including interest rate and currency exchange rate fluctuations, delay or of supplies and production, including as a result of interruptions or delays affecting supply chains on nt- mandated or market-driven price decreases for Novo Nordisk’s products, introduction of Novo Nordisk’s ability t o successfully market current and new products, exposure to product liability hereof, including on reimbursement, intellectual property protection and regulatory controls on eting practices, investments in and divestitures of domestic and foreign companies, unexpected ulture of compliance, and epidemics, pandemics or other public health crises, and the effects of the accuracy of forw ard-looking statements in this Annual Report 2021, reference is made to the ise any forward-looking statement after the distribution of this Annual Report 2021, whether as a
Share
Download PDF file
